logo
DoH unveils 'Genomics For Longevity' report

DoH unveils 'Genomics For Longevity' report

Al Etihad16-04-2025

16 Apr 2025 18:23
ABU DHABI (ALETIHAD)The Department of Health - Abu Dhabi (DoH), on Wednesday released a comprehensive report titled 'Genomics For Longevity', in collaboration with Oliver Wyman, a global management consulting firm and a business of Marsh McLennan (MMC), at the Abu Dhabi Global Health Week (ADGHW).The report explores the transformative potential of genomics in enhancing clinical outcomes, driving economic growth, and supporting Abu Dhabi's strategic vision for precision medicine.The report, unveiled under the theme 'Towards longevity: Redefined health and wellbeing,' highlights Abu Dhabi's role as a pioneer in precision medicine and longevity-focused healthcare.The 'Genomics For Longevity' report outlines a detailed framework and phased roadmap for integrating genomics across Abu Dhabi's healthcare systems. It emphasises the potential of genomics to revolutionise health by providing personalised treatment plans that cater to individual genetic profiles.The framework is centred on three strategic pillars: enabling technology, policy and governance and talent development, each designed to build a resilient and scalable genomics ecosystem.Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Science Sector at DoH, said, 'In a fast-evolving field like genomics, agility, and foresight are essential to ensure policies strike a balance between safety, innovation, and the constant flow of emerging evidence. This report is not just a roadmap, it is a call to action for policymakers, investors, and health system leaders to shape a new era of personalised care."Sumit Sharma, Partner and Head of Health and Life Sciences for India, Middle East & Africa at Oliver Wyman, said Abu Dhabi's commitment to integrating genomics into its healthcare system marks a transformative step towards precision medicine. This positions Abu Dhabi as a leader in longevity and data-driven medical care and promises significant economic growth and societal benefits.Dr. Nicole Sirotin, CEO of The Institute for Healthier Living Abu Dhabi (IHLAD) - the world's first licensed health longevity medicine centre and a contributor to the report, said, 'In a region where early onset of diabetes and cancer is prevalent, personalised prevention through genomics can be transformative. The fusion of cutting-edge research and rigorous clinical practice exemplifies Abu Dhabi's leading approach to precision, preventive healthcare.'The report highlights that by mapping genetic and epigenetic risk factors and intervening with precision therapies, chronic illnesses such as diabetes and cardiovascular disorders could be reduced by 20–30 percent on a population level. These efforts are underpinned by Abu Dhabi's robust digital infrastructure, tech-savvy population, and the Emirate's strategic prioritisation of public health.
Additionally, the Emirate Genome Programme, already one of the largest population sequencing efforts in the region with 800,000 genomes sequenced, lays a strong foundation for this transformation.
Source: Aletihad - Abu Dhabi

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Abu Dhabi, Abbott Partner to Boost Local Pharma Sector
Abu Dhabi, Abbott Partner to Boost Local Pharma Sector

TECHx

time9 hours ago

  • TECHx

Abu Dhabi, Abbott Partner to Boost Local Pharma Sector

Home » Smart Sectors » Healthcare » Abu Dhabi, Abbott Partner to Boost Local Pharma Sector The Department of Health, Abu Dhabi (DoH), the healthcare sector regulator in Abu Dhabi, announced a strategic partnership with global healthcare leader Abbott. The agreement was signed during the BIO International Convention held in Boston, USA. The partnership aims to localise pharmaceutical manufacturing in Abu Dhabi. It also focuses on advancing digital health solutions across the emirate. Officials revealed that the collaboration builds on Abu Dhabi's advanced life sciences infrastructure. This move supports the emirate's goal to reduce dependency on imports and strengthen supply chain resilience. It further reflects Abu Dhabi's commitment to fostering a self-sufficient and sustainable healthcare ecosystem. Dr. Noura Al Ghaithi, Undersecretary of DoH, stated that the partnership follows the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi. She added that the emirate is equipped with an integrated infrastructure to support local manufacturing and R&D. She said the agreement would position Abu Dhabi as a regional healthcare hub and leader in life sciences. According to her, aligning DoH's strategic vision with Abbott's global expertise will accelerate the delivery of innovative healthcare products and solutions. The collaboration is built around four key pillars: Localising Abbott's pharmaceutical portfolio and developing biosimilars. Advancing digital transformation through electronic patient information leaflets. Launching education programs to strengthen the healthcare workforce. Supporting regulatory alignment and joint R&D initiatives. Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant, reported that this partnership will enhance healthcare resilience and innovation in Abu Dhabi. He highlighted Abbott's ongoing commitment to the UAE's healthcare system. He noted that the partnership will also include digitising life sciences product information and launching training initiatives to build local capabilities. In addition, both parties will explore opportunities for joint research and development. DoH also reported that a high-level delegation has embarked on a strategic mission to the United States from 15 to 21 June 2025. The delegation will conduct over 20 meetings with public and private sector leaders. These meetings aim to promote knowledge exchange, attract investments, and sign new agreements that accelerate advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes: Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, and PureHealth. Etihad Cargo, New York University Abu Dhabi, Khalifa University, startAD, and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI). This announcement highlights Abu Dhabi's global ambitions in life sciences and healthcare innovation.

Abu Dhabi launches personalized weight loss programme; first in the Middle East
Abu Dhabi launches personalized weight loss programme; first in the Middle East

Filipino Times

time13 hours ago

  • Filipino Times

Abu Dhabi launches personalized weight loss programme; first in the Middle East

Abu Dhabi has launched the region's first Personalised Weight Management Programme to help residents manage their weight and prevent serious health problems. The program aims to lower the risk of diseases like type 2 diabetes, heart problems, and some cancers, improving the quality of life and helping people live longer, Abu Dhabi Media Office reported. An initiative of the Department of Health – Abu Dhabi (DoH) and Abu Dhabi Public Health Centre (ADPHC), this is the first program of its kind in the Middle East that combines online health tracking, insurance support, and medical care tailored to each person. 'Our focus is on health – not just weight. This programme supports our vision for an active, health-conscious community, empowering individuals through personalised and science-driven solutions,' Dr. Noura Al Ghaithi, Undersecretary of DoH, said. Those eligible include Thiqa insurance members aged 18 and above who are medically classified as overweight or obese. The plan includes early health checks, one-on-one coaching, diet and exercise guidance, and check-ups using the Sahatna health app.

DoH, Abbott unite to manufacture pharmaceuticals locally in Abu Dhabi
DoH, Abbott unite to manufacture pharmaceuticals locally in Abu Dhabi

Al Etihad

timea day ago

  • Al Etihad

DoH, Abbott unite to manufacture pharmaceuticals locally in Abu Dhabi

20 June 2025 22:37 BOSTON (WAM) Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Abbott, the global healthcare leader, entered a landmark partnership during the BIO International Convention in Boston agreement aims to localise the manufacturing of pharmaceuticals in Abu Dhabi and advance digital health Abu Dhabi's advanced life sciences infrastructure, this milestone reflects the emirate's proactive preparedness to reduce dependency on imports, strengthen supply chain resilience, and foster a sustainable, self-sufficient healthcare Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said, 'Following the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi, the emirate proved to be equipped with a holistic, integrated infrastructure that fosters local manufacturing and R&D, positioning it as a regional healthcare gateway and leader in life sciences." She added, "By integrating our strategic vision with Abbott's expertise, we aim to accelerate the development and deployment of innovative healthcare products and solutions, reducing time-to-market, improving healthcare outcomes, and ensuring that breakthrough therapies reach patients faster. This approach positions Abu Dhabi as a regional leader in fostering an agile, innovation-driven healthcare ecosystem that directly translates scientific advancements into tangible benefits for our community.'The strategic collaboration outlines a comprehensive plan focusing on four key pillars including localisation of Abbott's pharmaceutical portfolio, biosimilar development, digital transformation through electronic patient information leaflets, and a robust education and workforce development his part, Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant, said, 'Abbott is proud to announce a strategic collaboration with the Department of Health – Abu Dhabi, aimed at advancing healthcare resilience and innovation in Abu Dhabi." Bachir added, "Building on Abbott's long-standing commitment to the UAE's healthcare system, this partnership will focus on localising existing pharmaceutical products, and jointly exploring the development of biosimilars, supported by regulatory alignment. The collaboration also includes initiatives to digitise life science product information through electronic leaflets in alignment with the UAE's digital health strategy. Another key component of this collaboration is the development of education programs to build local capabilities. Additionally, Abbott and the Department of Health will evaluate opportunities for joint research and development to strengthen long-term healthcare sustainability in the UAE.'Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 15 - 21, 2025. The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the US, aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, startAD and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI).

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store